Jonathan L Halperin

Summary

Affiliation: Mount Sinai School of Medicine
Country: USA

Publications

  1. ncbi request reprint Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V)
    Jonathan L Halperin
    Zena and Michael A Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York, NY 10029 6574, USA
    Am Heart J 146:431-8. 2003
  2. ncbi request reprint Presidential address. Vascular medicine and biology: an evolving infrastructure
    Jonathan L Halperin
    The Zena and Michael A Wiener Cardiovascular Institute, Mount Sinai Medical Centre, New York, NY 10029 6574, USA
    Vasc Med 7:149-51. 2002
  3. ncbi request reprint Anticoagulation for atrial fibrillation in the elderly
    Jonathan L Halperin
    The Zena and Michael A Wiener Cardiovascular Institute, The Marie Josee and Henry R Kravis Center for Cardiovascular Health, Mount Sinai Medical Center, Fifth Avenue at 100th Street, New York, NY 10029, USA
    Am J Geriatr Cardiol 14:81-6. 2005
  4. ncbi request reprint Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor
    Jonathan L Halperin
    The Zena and Michael A Wiener Cardiovascular Institute, Mount Sinai Medical Center, 1 Gustave L Levy Place, New York, NY 10029 6574, USA
    Expert Rev Cardiovasc Ther 2:163-74. 2004
  5. ncbi request reprint Embracing a new paradigm to sustain vascular medicine
    Jonathan L Halperin
    Society for Vascular Medicine and Biology, The Zena and Michael A Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York, NY 10029 6574, USA
    Vasc Med 8:133-4. 2003
  6. doi request reprint Management of atrial fibrillation: direct factor IIa and Xa inhibitors or "warfarin shotgun"?
    Jonathan L Halperin
    The Cardiovascular Institute, Mount Sinai Medical Center, New York, NY, USA
    Mt Sinai J Med 79:705-20. 2012
  7. doi request reprint Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation
    Jeremy P Berman
    Division of Hospital Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
    Hosp Pract (1995) 41:37-48. 2013
  8. pmc Copy number variation and warfarin dosing: evaluation of CYP2C9, VKORC1, CYP4F2, GGCX and CALU
    Stuart A Scott
    Department of Genetics and Genomic Sciences, Box 1497, Mount Sinai School of Medicine, 1428 Madison Avenue, New York, NY 10029, USA
    Pharmacogenomics 13:297-307. 2012
  9. ncbi request reprint Warfarin pharmacogenetics: a controlled dose-response study in healthy subjects
    Daniella L Kadian-Dodov
    Vascular Medicine Section, The Zena and Michael A Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
    Vasc Med 18:290-7. 2013
  10. ncbi request reprint Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options
    Christopher J Varughese
    The Cardiovascular Institute, Mount Sinai Medical Center, Box 1030, Fifth Avenue at 100th Street, New York, NY 10029 6574, USA
    J Interv Card Electrophysiol 35:19-27. 2012

Detail Information

Publications76

  1. ncbi request reprint Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V)
    Jonathan L Halperin
    Zena and Michael A Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York, NY 10029 6574, USA
    Am Heart J 146:431-8. 2003
    ..0-3.0)...
  2. ncbi request reprint Presidential address. Vascular medicine and biology: an evolving infrastructure
    Jonathan L Halperin
    The Zena and Michael A Wiener Cardiovascular Institute, Mount Sinai Medical Centre, New York, NY 10029 6574, USA
    Vasc Med 7:149-51. 2002
  3. ncbi request reprint Anticoagulation for atrial fibrillation in the elderly
    Jonathan L Halperin
    The Zena and Michael A Wiener Cardiovascular Institute, The Marie Josee and Henry R Kravis Center for Cardiovascular Health, Mount Sinai Medical Center, Fifth Avenue at 100th Street, New York, NY 10029, USA
    Am J Geriatr Cardiol 14:81-6. 2005
    ..Other antithrombotic agents are under development as alternatives to warfarin, but sufficient data are not yet available to justify their clinical use in patients with atrial fibrillation...
  4. ncbi request reprint Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor
    Jonathan L Halperin
    The Zena and Michael A Wiener Cardiovascular Institute, Mount Sinai Medical Center, 1 Gustave L Levy Place, New York, NY 10029 6574, USA
    Expert Rev Cardiovasc Ther 2:163-74. 2004
    ..The open-label SPORTIF III trial confirmed the noninferiority of ximelagatran versus warfarin. Publication of the full results from SPORTIF V is pending...
  5. ncbi request reprint Embracing a new paradigm to sustain vascular medicine
    Jonathan L Halperin
    Society for Vascular Medicine and Biology, The Zena and Michael A Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York, NY 10029 6574, USA
    Vasc Med 8:133-4. 2003
  6. doi request reprint Management of atrial fibrillation: direct factor IIa and Xa inhibitors or "warfarin shotgun"?
    Jonathan L Halperin
    The Cardiovascular Institute, Mount Sinai Medical Center, New York, NY, USA
    Mt Sinai J Med 79:705-20. 2012
    ..However, important questions about patient management with these new agents have not been fully answered by studies completed to date and clinical inertia must yet be overcome...
  7. doi request reprint Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation
    Jeremy P Berman
    Division of Hospital Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
    Hosp Pract (1995) 41:37-48. 2013
    ..In this article, we provide an overview of the 3 novel oral anticoagulants for treating patients with AF and discuss the latest findings from subgroup analyses...
  8. pmc Copy number variation and warfarin dosing: evaluation of CYP2C9, VKORC1, CYP4F2, GGCX and CALU
    Stuart A Scott
    Department of Genetics and Genomic Sciences, Box 1497, Mount Sinai School of Medicine, 1428 Madison Avenue, New York, NY 10029, USA
    Pharmacogenomics 13:297-307. 2012
    ....
  9. ncbi request reprint Warfarin pharmacogenetics: a controlled dose-response study in healthy subjects
    Daniella L Kadian-Dodov
    Vascular Medicine Section, The Zena and Michael A Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
    Vasc Med 18:290-7. 2013
    ..In conclusion, genotype-guided warfarin-dosing algorithms may rely more on genetic variables in healthier individuals than in patients with clinical confounders...
  10. ncbi request reprint Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options
    Christopher J Varughese
    The Cardiovascular Institute, Mount Sinai Medical Center, Box 1030, Fifth Avenue at 100th Street, New York, NY 10029 6574, USA
    J Interv Card Electrophysiol 35:19-27. 2012
    ..This review provides an update on recent advancements in antithrombotic therapy for stroke prevention in patients with AF...
  11. doi request reprint Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial
    Vivek Y Reddy
    Helmsley Electrophysiology Center, The Cardiovascular Institute, Mount Sinai School of Medicine, One Gustave L Levy Place, Box 1030, New York, NY 10029, USA
    Circulation 127:720-9. 2013
    ....
  12. pmc Associations of LV hypertrophy with prevalent and incident valve calcification: Multi-Ethnic Study of Atherosclerosis
    Sammy Elmariah
    Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    JACC Cardiovasc Imaging 5:781-8. 2012
    ..The aim of this study was to evaluate the relationship between percentage of predicted left ventricular mass (%PredLVM) and valve calcification in the MESA (Multi-Ethnic Study of Atherosclerosis) study...
  13. ncbi request reprint Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation
    Jonathan L Halperin
    Mount Sinai School of Medicine, New York, New York 10029 6574, USA
    J Am Coll Cardiol 45:1-9. 2005
    ..In terms of preventing thromboembolism without hemorrhage, ximelagatran may have a more favorable benefit:risk profile than warfarin for patients with AF...
  14. pmc Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study
    Usman Baber
    Zena and Michael A Wiener Cardiovascular Institute and Marie Josee and Henry R Kravis Center for Cardiovascular Health, Mount Sinai School of Medicine, New York, NY, USA
    Circ Arrhythm Electrophysiol 4:26-32. 2011
    ..73 to 7.15) among those with stage 1 to 2, stage 3, and stage 4 to 5 CKD. The association between CKD and prevalent AF remained statistically significant after further multivariable adjustment and was consistent across numerous subgroups...
  15. pmc CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing
    Stuart A Scott
    Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine of New York University, New York, NY 10029, USA
    Pharmacogenomics 10:1243-55. 2009
    ..1173C>T) commonly found among Caucasians. Therefore, this study sought to identify other CYP2C9 and VKORC1 alleles important in warfarin dose variability and to determine their frequencies in different racial and ethnic groups...
  16. doi request reprint Antithrombotic therapy for patients with nonvalvular atrial fibrillation undergoing percutaneous coronary intervention: a review
    Andrew Krasner
    The Cardiovascular Institute, Mount Sinai Medical Center, New York, NY, USA
    Curr Cardiol Rep 15:378. 2013
    ....
  17. ncbi request reprint New anticoagulants for prevention of stroke in patients with atrial fibrillation
    Juan F Viles-Gonzalez
    Cardiovascular Institute, Mount Sinai Medical Center, New York, New York, USA
    J Cardiovasc Electrophysiol 22:948-55. 2011
    ..This review focuses on advances in the development of novel antithrombotic agents to provide practical information to clinicians on the use of these new drugs in patients with AF...
  18. doi request reprint What can ongoing clinical trials of anticoagulants demonstrate?
    Jonathan L Halperin
    Mount Sinai Medical Center, New York, New York 10029 6574, USA jonathan
    J Cardiovasc Med (Hagerstown) 10:610-5. 2009
    ..Evidence-based data from trials such as these will pave the way for new anticoagulants, with the goal of bringing optimum prophylactic therapy to those requiring anticoagulation...
  19. doi request reprint Stroke prevention in the high-risk atrial fibrillation patient: Medical management
    Michael Broukhim
    The Cardiovascular Institute, Mount Sinai Medical Center, New York, NY 10029, USA
    Curr Cardiol Rep 13:9-17. 2011
    ....
  20. ncbi request reprint Novel antiplatelet and anticoagulant agents in the cardiac care unit
    Vaani Panse Garg
    Department of Medicine, The Cardiovascular Institute, Mount Sinai Medical Center, Icahn School of Medicine at Mount Sinai, Fifth Avenue at 100th Street, New York, NY 10029 6574, USA
    Cardiol Clin 31:533-44, viii. 2013
    ..The clinical use of these drugs in cardiac intensive care is discussed, focusing on the management of acute coronary syndromes, ischemic stroke, atrial fibrillation, and venous thromboembolism. ..
  21. doi request reprint Changes in von Willebrand factor-cleaving protease (ADAMTS-13) in patients with aortic stenosis undergoing valve replacement or balloon valvuloplasty
    Jeffrey Bander
    Mount Sinai School of Medicine, Zena and Michael A Wiener Cardiovascular Institute, One Gustave L Levy Place, Box 1030, New York, NY 10029, USA
    Thromb Haemost 108:86-93. 2012
    ..These findings suggest that a portion of the haematologic benefit of AVR may be due to a postoperative decline in ADAMTS-13 rather than solely to relief of AS as previously thought...
  22. doi request reprint Ineligibility for anticoagulation in patients with atrial fibrillation
    Ian Del Conde
    The Cardiovascular Institute, Mount Sinai Medical Center, New York, NY, USA
    Am J Med 126:105-11. 2013
    ....
  23. doi request reprint Rate or rhythm control for atrial fibrillation: update and controversies
    Jason S Chinitz
    Zena and Michael A Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    Am J Med 125:1049-56. 2012
    ..Because safer and more effective pharmacologic and interventional therapies are now available, an individualized approach to atrial fibrillation management is essential...
  24. doi request reprint Aortic regurgitation: disease progression and management
    Seth H Goldbarg
    The Cardiovascular Institute, Box 1030, Mount Sinai Medical Center, One Gustave L Levy Place, New York, NY 10029, USA
    Nat Clin Pract Cardiovasc Med 5:269-79. 2008
    ..In this Review, we examine the epidemiology of AR in terms of the interplay between arterial and ventricular forces marking progression of disease over time, and analyze the practice guidelines regarding diagnosis and treatment...
  25. doi request reprint Recurrent orthostatic global amnesia in a patient with postoperative hyperfibrinogenemia
    Brett A Sealove
    Mount Sinai School of Medicine, New York, New York 10029, USA
    J Stroke Cerebrovasc Dis 17:241-3. 2008
    ..In conclusion, these observations implicate ischemia caused by hemodynamic vascular insufficiency as a possible cause of TGA...
  26. ncbi request reprint Left atrial appendage closure for stroke prevention in atrial fibrillation: state of the art and current challenges
    Tariqshah M Syed
    Department of Cardiology, Zena and Michael A Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York, NY 10029 6574, USA
    Nat Clin Pract Cardiovasc Med 4:428-35. 2007
    ..Here we discuss the LAA in relation to AF-related embolic stroke, and how LAA occlusion devices could be used in stroke prevention in patients who cannot tolerate chronic anticoagulant therapy...
  27. doi request reprint Peripheral pulmonary artery stenosis masquerading as pulmonary hypertension: a diagnostic and therapeutic challenge
    Tatyana Kushner
    Department of Internal Medicine, Mount Sinai Medical Center, New York, NY, USA
    Vasc Med 17:235-8. 2012
    ..Treatment consists of balloon angioplasty and stenting of the affected vessels, although the procedure can be complicated by reperfusion pulmonary edema...
  28. ncbi request reprint Limitation of the resting ankle-brachial index in symptomatic patients with peripheral arterial disease
    Russell Stein
    Zena and Michael A Wiener Cardiovascular Institute, Marie Josee and Henry R Kravis Center for Cardiovascular Health, Mount Sinai Medical Center, New York, NY 10029, USA
    Vasc Med 11:29-33. 2006
    ..Furthermore, when the ABI is normal at rest in patients with symptoms of intermittent claudication, exercise testing is recommended to enhance the sensitivity for detection of PAD...
  29. ncbi request reprint Unstable angina in a patient with anomalous origin of the left main coronary artery from the right sinus of Valsalva
    Biana Trost
    The Zena and Michael A Weiner Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY, USA
    Rev Cardiovasc Med 11:112-6. 2010
    ..Diagnosis and management of patients with this coronary anomaly are discussed...
  30. pmc Bisphosphonate Use and Prevalence of Valvular and Vascular Calcification in Women MESA (The Multi-Ethnic Study of Atherosclerosis)
    Sammy Elmariah
    Zena and Michael A Wiener Cardiovascular Institute, The Mount Sinai School of Medicine, New York, New York, USA
    J Am Coll Cardiol 56:1752-9. 2010
    ..the aim of this study was to determine whether nitrogen-containing bisphosphonate (NCBP) therapy is associated with the prevalence of cardiovascular calcification...
  31. ncbi request reprint Evaluation of patients with peripheral vascular disease
    Jonathan L Halperin
    The Zena and Michael A Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY 10029, USA
    Thromb Res 106:V303-11. 2002
    ..Angiography is indicated for mapping of the extent and location of arterial pathology prior to revascularization...
  32. ncbi request reprint Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    Daniel E Singer
    Clinical Epidemiology Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    Chest 133:546S-592S. 2008
    ..However, in patients without contraindications to anticoagulation, we suggest beginning IV heparin or LMWH at presentation (Grade 2C)...
  33. ncbi request reprint "Triple therapy" or triple threat? Balancing the risks of antithrombotic therapy for patients with atrial fibrillation and coronary stents
    Steven Francescone
    J Am Coll Cardiol 51:826-7. 2008
  34. ncbi request reprint 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaborat
    Elliott M Antman
    Circulation 117:296-329. 2008
  35. ncbi request reprint Patent foramen ovale and recurrent stroke: another paradoxical twist
    Jonathan L Halperin
    Circulation 105:2580-2. 2002
  36. ncbi request reprint Confronting atrial fibrillation in the elderly: stroke risk stratification and emerging antithrombotic therapies
    Samantha H Strong
    Kaiser Permanente, USA
    Geriatrics 62:22-7. 2007
    ..In the future, new anticoagulants that are safer and easier to administer than warfarin will improve the benefit/risk burden for elderly patients with AF...
  37. ncbi request reprint American Heart Association/American College of Cardiology Foundation guide to warfarin therapy
    Jack Hirsh
    Circulation 107:1692-711. 2003
  38. ncbi request reprint Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)
    Ronald S Freudenberger
    Department of Medicine, Robert Wood Johnson Medical School, Suite 6100, 125 Paterson St, New Brunswick, NJ 08903, USA
    Circulation 115:2637-41. 2007
    ..In the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), 2521 patients with moderate heart failure were randomized to receive amiodarone, implanted cardioverter-defibrillators (ICDs), or placebo...
  39. ncbi request reprint Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials
    Mardi Gomberg-Maitland
    Department of Medicine, Section of Cardiology, University of Chicago Hospitals, University of Chicago, 5841 S Maryland Avenue, MC2016, Chicago, IL 60637, USA
    Eur Heart J 27:1947-53. 2006
    ..The risk of stroke is greater among women with atrial fibrillation (AF) than men. Warfarin protects against stroke, but treatment-related bleeding occurs more often in women than in men...
  40. ncbi request reprint Efficacy of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation at 6 months: a randomized controlled trial
    Allan L Klein
    Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am Heart J 151:380-9. 2006
    ..We compared a transesophageal echocardiography (TEE)-guided strategy with a conventional strategy in patients with AF > 2 days' duration undergoing electrical cardioversion over a 6-month follow-up...
  41. ncbi request reprint Prevention of stroke in patients with atrial fibrillation
    S Bertil Olsson
    Department of Cardiology, University Hospital, Lund, Sweden
    Semin Vasc Med 5:285-92. 2005
    ....
  42. ncbi request reprint Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial
    Gregory W Albers
    Stanford Stroke Center, Palo Alto, Calif, USA
    JAMA 293:690-8. 2005
    ..In patients with nonvalvular atrial fibrillation, warfarin prevents ischemic stroke, but dose adjustment, coagulation monitoring, and bleeding limit its use...
  43. ncbi request reprint Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
    Daniel E Singer
    Clinical Epidemiology Unit, S50 9, Massachusetts General Hospital, Boston, MA 02114, USA
    Chest 126:429S-456S. 2004
    ..However, in patients without contraindications to anticoagulation, we suggest beginning IV heparin or low molecular weight heparin at presentation (Grade 2C)...
  44. ncbi request reprint Lessons from the Stroke Prevention in Atrial Fibrillation trials
    Robert G Hart
    Department of Medicine Neurology, University of Texas Health Science Center, 7703 Floyd Curl Drive MC 7883, San Antonio, Texas 78229 3900, USA
    Ann Intern Med 138:831-8. 2003
    ..For patients at moderate risk for stroke, patient preferences and access to reliable anticoagulation monitoring are particularly relevant...
  45. ncbi request reprint American Heart Association/American College of Cardiology Foundation guide to warfarin therapy
    Jack Hirsh
    J Am Coll Cardiol 41:1633-52. 2003
  46. ncbi request reprint Trials and tribulations of noninferiority: the ximelagatran experience
    Gregory W Albers
    J Am Coll Cardiol 48:1058; author reply 1059. 2006
  47. ncbi request reprint Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials
    Greg C Flaker
    Department of Medicine, University of Missouri Columbia, Columbia, MO, USA
    Am Heart J 152:967-73. 2006
    ..Aspirin is used in combination with anticoagulant therapy in patients with atrial fibrillation (AF), but evidence of additional efficacy is not available...
  48. doi request reprint 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
    Elliott M Antman
    J Am Coll Cardiol 51:210-47. 2008
  49. ncbi request reprint ACC/AHA Guidelines for the Management of Patients with Peripheral Arterial Disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Associations for Vascular Surgery/Society for Vascular Surgery, Society
    Alan T Hirsch
    J Vasc Interv Radiol 17:1383-97; quiz 1398. 2006
  50. ncbi request reprint ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Managem
    Elliott M Antman
    Circulation 110:e82-292. 2004
  51. ncbi request reprint ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Arte
    Kim A Eagle
    J Am Coll Cardiol 44:e213-310. 2004
  52. ncbi request reprint ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999
    Elliott M Antman
    Circulation 110:588-636. 2004
  53. ncbi request reprint ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice
    Valentin Fuster
    Circulation 114:e257-354. 2006
  54. ncbi request reprint ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Com
    Robert L McNamara
    J Am Coll Cardiol 44:475-95. 2004
  55. ncbi request reprint ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Com
    Robert L McNamara
    Circulation 109:3223-43. 2004
  56. ncbi request reprint Obliteration of the left atrial appendage for prevention of thromboembolism
    Jonathan L Halperin
    J Am Coll Cardiol 42:1259-61. 2003
  57. ncbi request reprint Active-control clinical trials to establish equivalence or noninferiority: methodological and statistical concepts linked to quality
    Mardi Gomberg-Maitland
    Rush Heart Institute for Pulmonary Heart Disease, Rush School of Medicine, Chicago, Ill 60612 3824, USA
    Am Heart J 146:398-403. 2003
    ..A guideline is proposed as a standard approach for reporting to facilitate qualitative assessment of the methodology of these trials...
  58. ncbi request reprint Postgraduate training in vascular medicine: proposed requirements and standards
    Mark A Creager
    Harvard Medical School, Boston, MA, USA
    Vasc Med 8:47-52. 2003
  59. ncbi request reprint Should we use anticoagulation for patients with chronic heart failure?
    Ronald S Freudenberger
    Division of Cardiovascular Diseases and Hypertension, Department of Medicine, Robert Wood Johnson Medical School, 125 Paterson Street, New Brunswick, NJ 08901, USA
    Nat Clin Pract Cardiovasc Med 3:580-1. 2006
  60. ncbi request reprint Meeting the challenge of peripheral arterial disease
    Jonathan L Halperin
    Arch Intern Med 163:877-8. 2003
  61. ncbi request reprint ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise th
    Jeffrey L Anderson
    Circulation 116:e148-304. 2007
  62. ncbi request reprint ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise th
    Jeffrey L Anderson
    J Am Coll Cardiol 50:e1-e157. 2007
  63. doi request reprint ACC/AHA/Physician Consortium 2008 clinical performance measures for adults with nonvalvular atrial fibrillation or atrial flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physici
    N A Mark Estes
    Circulation 117:1101-20. 2008
  64. doi request reprint 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines
    Spencer B King
    J Am Coll Cardiol 51:172-209. 2008
  65. doi request reprint ACC/AHA/Physician Consortium 2008 Clinical Performance Measures for Adults with Nonvalvular Atrial Fibrillation or Atrial Flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physici
    N A Mark Estes
    J Am Coll Cardiol 51:865-84. 2008
  66. ncbi request reprint ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Com
    Douglas P Zipes
    Circulation 114:e385-484. 2006
  67. doi request reprint ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities
    Andrew E Epstein
    Heart Rhythm 5:e1-62. 2008
  68. doi request reprint ACC/AHA/HRS 2008 guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: executive summary
    Andrew E Epstein
    Heart Rhythm 5:934-55. 2008
  69. ncbi request reprint 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence an
    Spencer B King
    Circulation 117:261-95. 2008
  70. ncbi request reprint ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Comm
    Valentin Fuster
    J Am Coll Cardiol 48:854-906. 2006
  71. ncbi request reprint ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee fo
    Valentin Fuster
    France
    Europace 8:651-745. 2006
  72. ncbi request reprint ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Sur
    Alan T Hirsch
    Circulation 113:e463-654. 2006
  73. ncbi request reprint ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vas
    Alan T Hirsch
    J Am Coll Cardiol 47:1239-312. 2006
  74. ncbi request reprint [ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--excutive summary]
    Valentin Fuster
    Rev Port Cardiol 26:383-446. 2007
  75. ncbi request reprint [Guidelines for the management of patients with atrial fibrillation. Executive summary]
    Valentin Fuster
    Rev Esp Cardiol 59:1329. 2006